Anti-idiotypic antibody abagovomab in advanced ovarian cancer.

Abstract

Ovarian cancer is the fifth most common malignancy with approximately 22,000 newly diagnosed cases each year in the USA. Standard of care after cytoreductive surgery is the application of carboplatin and paclitaxel. The newly developed anti-idiotypic monoclonal antibody abagovomab demonstrated promising results in Phase I/II trials. This new type of drug is currently being tested in a Phase II/III trial in ovarian cancer patients with a complete response after standard first-line chemotherapy. Activating the cancer hosts immune system is a new strategy that is worth being pursued in the fight against ovarian cancer.

• Authors: Dirk O Bauerschlag, Christian Schem, Klaus Baumann, Philip Harter, Felix Hilpert, Uwe Wagner, Andreas du Bois, Jakobus Pfisterer
• Journal: Future oncology (London, England) (Future Oncol) Vol. 4 Issue 6 Pg. 769-73 (Dec 2008) ISSN: 1744-8301 [Electronic] England
• PMID: 19086842 (Publication Type: Journal Article, Review)

Chemical References

• Antibodies, Anti-Idiotypic
• Antibodies, Monoclonal
• Antibodies, Monoclonal, Murine-Derived
• Antineoplastic Agents
• abagovomab

Topics

• Antibodies, Anti-Idiotypic (therapeutic use)
• Antibodies, Monoclonal
• Antibodies, Monoclonal, Murine-Derived
• Antineoplastic Agents (therapeutic use)
• Clinical Trials as Topic
• Female
• Humans
• Ovarian Neoplasms (drug therapy)